Northwest Biotherapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 95.2% | 250.6% | -224.7% |
| FY2024 | 88.7% | 263.4% | -313.4% |
| FY2025 | 99.8% | 25,278.2% | -74.0% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2023 | 95.2% | 250.6% | -224.7% |
| FY2024 | 88.7% | 263.4% | -313.4% |
| FY2025 | 99.8% | 25,278.2% | -74.0% |